Phase 2/3 Clinical Trials & Research Summary
CBL-514 is a novel first-in-class small molecule investigational drug designed to induce targeted reduction of subcutaneous and visceral fat through adipocyte apoptosis (programmed fat cell death). Unlike traditional lipolytic agents or invasive procedures that result in indiscriminate tissue necrosis, CBL-514 selectively activates apoptotic pathways in fat cells, while sparing adjacent nerve, vascular, and muscular tissues.
CBL-514 is now in global phase 3 clinical trials and has attracted much attention in the fields of aesthetic medicine, metabolic therapeutics and laboratory cellular biology.
1. The Science: Mechanism of Action (Adipocyte Apoptosis vs Necrosis)
To understand why CBL-514 is a paradigm shift in body contouring and metabolic science, researchers differentiated between two mechanisms of cell elimination:
| Feature | Older Compounds (e.g., Deoxycholic Acid / Kybella) | CBL-514 (Small Molecule) | | :— | :— | :— | | Primary Mechanism | Cytolytic / Tissue Necrosis | Targeted Adipocyte Apoptosis | | Cell Death Process | Cell lysis resulting in membrane rupture | Controlled, programd cell death | | Surrounding Tissue Impact | Can damage adjacent nerves, skin, and vascular walls | Selective to fat cells; preserves adjacent structures | | Inflammatory Response | Severe swelling, erythema, and prolonged induration | Mild-to-moderate, transient localised inflammation | | Long-Term Cell Count | Variable | Permanent reduction in treated adipocyte numbers |
CBL-514, when administered to target adipose tissue, triggers internal biochemical signalling cascades leading to the natural degradation of mature adipocytes. The macrophage system removes cellular debris via endogenous phagocytic pathways without the release of toxic intracellular contents into extracellular space.
2. Clinical Trial Milestones & Academic Validation
CBL-514 has been extensively studied in clinical trials in the United States, Australia and the Asia Pacific:
Phase 2 Clinical Trials (CBL-0204 & CBL-0205)
Phase 2b data in peer-reviewed journals like the Aesthetic Surgery Journal (ASJ) revealed:* CBL-514 was effective in at least 75% of subjects (minimum 1 grade improvement in Abdominal Fat Rating Scale [AFRS])
- MRI imaging at high resolution confirmed statistically significant, sustained reductions in subcutaneous fat volume.
Favourable safety profile with no drug-related severe adverse events (SAEs) or systemic toxicity observed.
Phase 3 Global Pivotal Studies (SUPREME-01 / NCT07140939)
Following the success of Phase 2, CBL-514 progressed into pivotal Phase 3 trials for the reduction of large-surface area subcutaneous fat in a broad range of patient populations.
Combination Studies with GLP-1 Receptor Agonists (CBL-0201WR)
One of the most consequential developments in metabolic pharmacology is the clearance of Phase 2 IND trials pairing CBL-514 with GLP-1/GIP agonists such as Tirzepatide (Zepbound). GLP-1 drugs promote systemic weight loss by reducing adipocyte size, but patients often rapidly regain weight following discontinuation of therapy due to unchanged overall adipocyte number. The double impact of systemic appetite suppression and local adipocyte apoptosis by CBL-514 mitigates the age-old problem of fat rebound after treatment.
3. Other than Body Sculpting Investigational Indications
While the primary aim is localised fat reduction, CBL-514 is actively evaluated for complex pathologies involving abnormal deposits of adipose tissue:
- Dercum’s Disease (Adiposis Dolorosa) – A rare and painful disorder of painful subcutaneous lipoma. CBL-514 received FDA Orphan Drug Designation and Fast Track Designation based on Phase 2 trial data demonstrating significant reductions in lipoma size and pain scores.
- Cellulite (Oedematous Fibrosclerotic Panniculopathy): Phase 2 trials (CBL-0201EFP) met primary endpoints showing tangible smoothing of skin topography.
4. Lab Handling, Purity & Sourcing for Research
For academic institutions, contract research organisations (CROs) and analytical laboratories studying apoptosis cascades:
- Analytical Purity: Research compounds must be confirmed by High Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to be $\ge 98.0%$ pure.
Storage Protocol: Lyophilised CBL-514 vials should be kept in the dark at $-20^\circ\text{C}$ to $2-8^\circ\text{C}$. Solutions should be used immediately after reconstitution with sterile bacteriostatic water or laboratory buffer or stored according to stability protocol in the experiment. > Research Sourcing Notice: Certified laboratory batches of research-grade CBL-514 injection with verified HPLC Certificates of Analysis (COA) can be purchased directly through the Caliway Biopharma Research Store.
5. Frequently Asked Questions (FAQ) #### Is CBL-514 a peptide?
CBL-514 is a synthetic small molecule entity designed for localised, selective adipose targeting, whereas independent researchers typically group CBL-514 with aesthetic and metabolic peptides.
How does CBL-514 compare to surgery (Liposuction)?
Liposuction is an invasive surgery requiring anaesthesia, cannulas, and time off for recovery. CBL-514 is an injectable formulation that causes the cells to die by apoptosis without the need for surgical incision or trauma to structural tissue.
Where can qualified researchers obtain CBL-514?
Authorised laboratories and scientific investigators can purchase high-purity CBL-514 research vials online with delivery worldwide.
